7 citations · 12 across the 4 of their papers we have counts for
4 papers · 1 filter
Design Considerations for a Phase II platform trial in Major Depressive Disorder
Michaela Maria Freitag, Dario Zocholl, Elias Laurin Meyer +5
Major Depressive Disorder (MDD) is one of the most common causes of disability worldwide. Unfortunately, about one-third of patients do not benefit sufficiently from available trea…
Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints
Elias Laurin Meyer, Peter Mesenbrink, Nicholas A. Di Prospero +5
Non-alcoholic steatohepatitis (NASH) is the progressive form of nonalcoholic fatty liver disease (NAFLD) and a disease with high unmet medical need. Platform trials provide great b…
Decision rules for identifying combination therapies in open-entry, randomized controlled platform trials
Elias Laurin Meyer, Peter Mesenbrink, Cornelia Dunger-Baldauf +3
Platform trials have become increasingly popular for drug development programs, attracting interest from statisticians, clinicians and regulatory agencies. Many statistical questio…
Adding experimental treatment arms to Multi-Arm Multi-Stage platform trials in progress
Thomas Burnett, Franz König, Thomas Jaki
Multi-Arm Multi-Stage (MAMS) platform trials are an efficient tool for the comparison of several treatments. Suppose we wish to add a treatment to a trial already in progress, to a…